Critical Analysis: BioHarvest Sciences (BHST) versus The Competition

BioHarvest Sciences (NASDAQ:BHST) is one of 55 publicly-traded companies in the “Personal Care Products” industry, but how does it weigh in compared to its rivals? We will compare BioHarvest Sciences to similar businesses based on the strength of its risk, profitability, earnings, dividends, institutional ownership, valuation and analyst recommendations.

Institutional & Insider Ownership

48.6% of shares of all “Personal Care Products” companies are held by institutional investors. 11.7% of shares of all “Personal Care Products” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares BioHarvest Sciences and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioHarvest Sciences	$34.51 million	-$11.14 million	-2.89
BioHarvest Sciences Competitors	$8.28 billion	$1.11 billion	8.40

BioHarvest Sciences’ rivals have higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

BioHarvest Sciences has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, BioHarvest Sciences’ rivals have a beta of 0.80, suggesting that their average share price is 20% less volatile than the S&P 500.

Profitability

This table compares BioHarvest Sciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioHarvest Sciences	-31.21%	-58.30%	-25.60%
BioHarvest Sciences Competitors	-4.71%	-66.70%	-0.51%

Analyst Ratings

This is a breakdown of current ratings for BioHarvest Sciences and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioHarvest Sciences	1	0	2	0	2.33
BioHarvest Sciences Competitors	904	2943	3663	229	2.42

BioHarvest Sciences currently has a consensus target price of $6.50, indicating a potential upside of 331.89%. As a group, “Personal Care Products” companies have a potential upside of 0.39%. Given BioHarvest Sciences’ higher possible upside, equities analysts clearly believe BioHarvest Sciences is more favorable than its rivals.

Summary

BioHarvest Sciences rivals beat BioHarvest Sciences on 9 of the 13 factors compared.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology company developing health and wellness products through its proprietary Botanical Synthesis technology. The platform is designed to produce plant-based compounds in controlled environments without relying on conventional agricultural cultivation of the whole plant, with the goal of preserving targeted botanical molecules and improving production consistency. The company’s primary commercial product is VINIA, a dietary supplement made from a proprietary red grape cell culture and marketed for its polyphenol content and potential cardiovascular and general wellness benefits.